Most organizations say they are committed to innovation. Fewer have a clear-eyed view of what happens to an idea between the moment it is conceived and the moment a customer pays for it — and why so many good ideas fail to complete that journey.
The product value chain is the framework for understanding that journey. It maps the sequence of functions, decisions, and investments that transform an idea into commercial revenue. Understanding it is not an academic exercise. It is the difference between organizations that successfully commercialize innovation and those that generate excellent science that never finds a market.
What the Value Chain Actually Is
The term value chain is often used loosely. In the context of product development, it refers to something specific: the cumulative increase in a product’s commercial value as it moves from ideation through development, manufacturing, and into the hands of customers.
The key word is cumulative. Value does not appear at launch. It builds — slowly at first, then with increasing momentum as each function in the chain adds its contribution. An idea has potential but no value. A validated proof of concept has more. A manufactured, regulated, positioned, and commercially available product has significant value. But only if each stage of the chain executes its role and hands off cleanly to the next.
This is where most organizations underperform. Not at any single stage, but at the transitions between them.
The Stages and What Each One Adds
The value chain moves through eight stages, each adding something distinct.
Ideation and Discovery is where concepts are generated, early-stage R&D begins, and unmet needs are identified. The value added is potential — the seed of future commercial value. The common failure here is generating ideas without a market grounding or commercial filter.
Proof of Concept is where feasibility is tested, preliminary data is generated, and early IP is filed. A successful PoC materially reduces risk and validates that potential. The failure mode is declaring a PoC on technical criteria alone without testing commercial viability.
Development is where formulation, engineering, and design validation happen — and where regulatory strategy should be actively shaping decisions. This stage commits investment and produces a buildable product. Organizations that address regulatory requirements too late, or exclude commercial input from development, pay for it here.
Manufacturing Scale-Up is where process development, tech transfer, and GMP production occur. This is where value becomes locked into physical form. Scale-up failures — when a process that worked at bench scale does not reproduce at production scale — are among the most costly and time-consuming problems in product development.
Regulatory and Quality is where submissions are made, approvals are granted, and QMS compliance is maintained. This stage produces a market-legal product. Organizations that treat regulatory as a late-stage gate rather than a continuous function routinely discover they have developed products they cannot approve as designed.
Marketing and Positioning is where the value proposition is built, markets are segmented, and launch strategy is defined. This stage produces a marketable product — one that customers can find and understand. Positioning built on internal assumptions, without the customer voice embedded, consistently underperforms.
Sales and Commercialization is where customers are acquired, channels are activated, and accounts are managed. This is where revenue is realized. The failure mode is a sales force that is undertrained or cannot translate complex clinical and technical value into the conversation that matters — the two minutes with a physician, procurement officer, or formulary committee.
Customer Adoption is the final and most generative stage. It validates the commercial value that the entire chain was built to create — and, when managed well, seeds the next innovation cycle through feedback, advocacy, and identification of unmet needs the original product did not address.
The Handoff Problem
The transitions between stages are where value is most frequently lost, and they are the least managed part of most product development processes.
When R&D hands off to development, critical knowledge about why certain formulations work — and others do not — often fails to transfer. When development hands off to manufacturing scale-up, process assumptions that held at bench scale prove incorrect at production scale. When regulatory hands off to marketing, the approved label constrains positioning in ways the commercial team was not prepared for. When marketing hands off to sales, the message that was carefully crafted becomes garbled in transmission.
Each of these handoffs is a risk event. Organizations that treat them as administrative milestones — sign the document, move to the next phase — consistently lose value that took significant investment to create.
What This Means in Life Sciences
In life sciences and healthcare, the value chain carries complexity that makes handoff discipline even more consequential.
Regulatory requirements are not add-ons at the end of development — they shape what can be built, how it must be tested, what claims can be made, and what post-market obligations apply. Organizations that treat regulatory as a late-stage gate consistently discover that they have approved products they cannot position as intended.
For biologic and cell and gene therapy products, manufacturing is not a commodity function. It is a core technical competency with direct impact on product quality, patient safety, and cost of goods. A product that cannot be manufactured reproducibly at scale is not a product. It is a promising experiment.
And in life sciences, customer adoption is not a passive outcome of making a product available. Physicians, payers, health systems, and patients each have distinct adoption barriers. The commercial team that does not understand those barriers specifically — not generically — will underperform against the product’s true potential.
Where Value Most Commonly Leaks
Across MKA’s client engagements, value chain failures cluster around three patterns.
The orphaned innovation: a technically excellent product that reaches regulatory approval but was never grounded in a real commercial strategy. The science is sound. The market analysis is thin. The organization launches into a market it does not understand well and is surprised when adoption is slow.
The late regulatory discovery: a product developed to specification, then submitted for approval, at which point the team discovers that the pathway they assumed was available is not. The result is a reformulation, a new submission, or a program that cannot be rescued on the original timeline or budget.
The broken commercial handoff: a well-developed, well-approved product that reaches the sales force and immediately loses coherence. The value proposition that made sense to the scientists and marketers who built it does not translate into the conversation that drives an actual purchase decision. The product underperforms not because it is wrong for the market, but because the chain from development insight to customer conversation was never completed.
The Practical Implication
Understanding the product value chain is not just useful for product managers. It is essential for any organizational leader who makes resource allocation decisions, sets development timelines, or evaluates commercial performance.
When a product underperforms, the instinct is to ask what is wrong with the product or the sales team. The right question is: where in the chain did value stop accumulating? That question almost always points to a structural answer — a handoff that was never designed, a function that was excluded too early, an assumption that was never tested against market reality.
The value chain is not a linear flowchart. It is a diagnostic instrument. Organizations that use it that way build products that succeed. Those that treat it as a background concept tend to repeat the same failures at significant cost.
MKA Insights works with life sciences and healthcare organizations on product development strategy, commercial planning, and value chain diagnostics. Contact us.